JP2023533447A5 - - Google Patents

Info

Publication number
JP2023533447A5
JP2023533447A5 JP2022578991A JP2022578991A JP2023533447A5 JP 2023533447 A5 JP2023533447 A5 JP 2023533447A5 JP 2022578991 A JP2022578991 A JP 2022578991A JP 2022578991 A JP2022578991 A JP 2022578991A JP 2023533447 A5 JP2023533447 A5 JP 2023533447A5
Authority
JP
Japan
Prior art keywords
combination
unsubstituted
use according
independently
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533447A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/037473 external-priority patent/WO2021262484A1/en
Publication of JP2023533447A publication Critical patent/JP2023533447A/ja
Publication of JP2023533447A5 publication Critical patent/JP2023533447A5/ja
Pending legal-status Critical Current

Links

JP2022578991A 2020-06-24 2021-06-15 がんを処置する併用療法 Pending JP2023533447A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063043342P 2020-06-24 2020-06-24
US63/043,342 2020-06-24
US202163162184P 2021-03-17 2021-03-17
US63/162,184 2021-03-17
PCT/US2021/037473 WO2021262484A1 (en) 2020-06-24 2021-06-15 Combination therapy for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2023533447A JP2023533447A (ja) 2023-08-03
JP2023533447A5 true JP2023533447A5 (enExample) 2024-06-25

Family

ID=79281702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578991A Pending JP2023533447A (ja) 2020-06-24 2021-06-15 がんを処置する併用療法

Country Status (10)

Country Link
US (2) US11938124B2 (enExample)
EP (1) EP4171548A4 (enExample)
JP (1) JP2023533447A (enExample)
KR (1) KR20230028484A (enExample)
CN (1) CN116096704A (enExample)
AU (1) AU2021297716A1 (enExample)
CA (1) CA3183081A1 (enExample)
IL (1) IL298592A (enExample)
MX (1) MX2022015793A (enExample)
WO (1) WO2021262484A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12570645B2 (en) 2020-06-22 2026-03-10 Pmv Pharmaceuticals, Inc. Uses of p53 x-ray co-crystal structures
CN116249689A (zh) * 2020-06-24 2023-06-09 皮姆维制药公司 用于再激活突变p53的化合物的伴随诊断工具
WO2022213975A1 (en) * 2021-04-08 2022-10-13 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
UY39890A (es) * 2021-08-10 2023-03-31 Jacobio Pharmaceuticals Co Ltd Compuestos con diana en mutante de p53
CN117916230A (zh) * 2021-08-27 2024-04-19 杭州紫晶医药科技有限公司 作为p53调节剂的化合物
WO2023147419A2 (en) * 2022-01-27 2023-08-03 Pmv Pharmaceuticals, Inc. Deuterated compounds for restoring mutant p53 function
EP4525859A4 (en) * 2022-05-16 2026-04-29 Pmv Pharmaceuticals Inc METHODS AND COMPOUNDS FOR RESTORING A P53 MUTANT FUNCTION
WO2024017384A1 (zh) * 2022-07-22 2024-01-25 深圳众格生物科技有限公司 恢复p53突变功能的化合物及其应用
WO2024041503A1 (en) * 2022-08-22 2024-02-29 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53
AR130828A1 (es) * 2022-10-21 2025-01-22 Scorpion Therapeutics Inc Método para tratar el cáncer
CN120265637A (zh) * 2022-12-08 2025-07-04 北京加科思新药研发有限公司 靶向p53突变体的化合物
CN121399109A (zh) * 2023-06-27 2026-01-23 长春金赛药业有限责任公司 p53-Y220C选择性小分子重激活剂化合物、药物组合物及其用途
WO2025031471A1 (zh) * 2023-08-09 2025-02-13 德睿智药(苏州)新药研发有限公司 用于调节p53功能的新型杂环类化合物
AU2024295989B2 (en) * 2023-10-20 2026-08-13 Nutshell Therapeutics (Shanghai) Co., Ltd. N-sulfonamide nitrogen-containing fused heterocyclic compound, and application thereof
WO2026067649A1 (zh) * 2024-09-27 2026-04-02 奇树医药公司 恢复p53突变功能的化合物及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302589A (en) 1980-05-08 1981-11-24 American Cyanamid Company Cis-mono and disubstituted-2-methyl-3-[(piperazinyl) and (piperidino)ethyl]indolines, intermediates for their preparation and methods of preparation
WO2000032175A2 (en) 1998-12-02 2000-06-08 Pfizer Products Inc. METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
US6770652B2 (en) 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
CA2511625A1 (en) * 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
US7601714B2 (en) 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
EP2268658B1 (en) 2008-03-13 2015-12-09 Universita'Degli Studi di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
EP2367817A4 (en) 2008-12-03 2012-05-09 Via Pharmaceuticals Inc INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
HUE027755T2 (en) 2009-03-27 2016-11-28 Merck Sharp & Dohme Inhibitors of hepatitis C virus replication
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
RU2598842C2 (ru) 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
GB201110390D0 (en) 2011-06-20 2011-08-03 Medical Res Council Compounds for use in stabilising p53 mutants
SG10201601840RA (en) 2011-09-09 2016-04-28 Agency Science Tech & Res P53 activating peptides
WO2013101911A2 (en) 2011-12-28 2013-07-04 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
US8822689B2 (en) 2012-09-19 2014-09-02 Merial Limited Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof
EP3079689A4 (en) * 2013-12-10 2017-08-09 Incuron LLC Methods of modulating various biomarkers with curaxins
EP3145512B1 (en) 2014-05-19 2019-07-17 Jiangsu Hengrui Medicine Co., Ltd. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
WO2015179799A1 (en) 2014-05-22 2015-11-26 The General Hospital Corporation DD1alpha RECEPTOR AND USES THEREOF IN IMMUNE DISORDERS
WO2016004513A1 (en) 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
CN104672241B (zh) 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
AU2016315878A1 (en) 2015-09-03 2018-03-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20190038713A1 (en) * 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
MX383904B (es) * 2016-02-19 2025-03-14 Pmv Pharmaceuticals Inc Métodos y composiciones para restablecer la función de p53 mutante.
US10870640B2 (en) * 2016-04-08 2020-12-22 Institute For Cancer Research Prodigiosin analogs and methods of use
US20180008688A1 (en) * 2016-07-06 2018-01-11 Augusta University Research Institute, Inc. Method and compositions for enhancing immunotherapeutic treatment of a cancer
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
US11286927B2 (en) * 2017-03-23 2022-03-29 Nidec Tosok Corporation Pump device
US20200071326A1 (en) 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
US20190002460A1 (en) 2017-06-28 2019-01-03 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
US11203598B2 (en) * 2018-01-24 2021-12-21 Institute For Cancer Research Compounds for repressing cancer cell growth
US20200397738A1 (en) 2018-02-27 2020-12-24 President And Fellows Of Harvard College Methods for treating cancer and protecting renewable tissues
SG11202102338TA (en) * 2018-09-20 2021-04-29 Aprea Therapeutics Ab Quinuclidine-3-one derivatives and their use in cancer treatment
WO2020077039A1 (en) * 2018-10-12 2020-04-16 Synergene Therapeutics, Inc. Methods for reducing side effects of immunotherapy
WO2020198734A1 (en) * 2019-03-28 2020-10-01 The Penn State Research Foundation Methods, compositions relating to treatment of cancer
WO2021053155A1 (en) 2019-09-18 2021-03-25 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
US11814373B2 (en) 2019-09-23 2023-11-14 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
US12692273B2 (en) 2019-11-01 2026-07-28 The Regents Of The University Of California p53 modulators and uses thereof
TW202128156A (zh) 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021207598A1 (en) 2020-04-10 2021-10-14 Aprea Therapeutics, Inc. Combination treatment with an agonist of p53 and a second therapeutic agent
EP4149459A4 (en) * 2020-05-12 2024-05-22 PMV Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION
US12570645B2 (en) 2020-06-22 2026-03-10 Pmv Pharmaceuticals, Inc. Uses of p53 x-ray co-crystal structures
WO2021262483A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
CN116249689A (zh) 2020-06-24 2023-06-09 皮姆维制药公司 用于再激活突变p53的化合物的伴随诊断工具

Similar Documents

Publication Publication Date Title
CN105102451B (zh) N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途
CN105189453B (zh) 氨磺酰基‑芳基酰胺及其作为用于乙型肝炎治疗的药物的用途
JP7611278B2 (ja) 金属酵素阻害剤化合物
JP7308816B2 (ja) ビスアミド筋節活性化化合物及びその使用
JP4024309B2 (ja) 新規な感染症治療薬
JP2021534124A5 (enExample)
JP2009542716A5 (enExample)
JPWO1998017625A1 (ja) 新規な感染症治療薬
JP2006507326A5 (enExample)
TW201617331A (zh) 異吲哚啉衍生物
US8658639B2 (en) N-substituted-cyclic amino derivative
JP2013542267A5 (enExample)
KR102691642B1 (ko) 헤테로사이클릭 화합물 및 이의 박테리아 감염의 예방 또는 치료 용도
UA129029C2 (uk) Сполуки піролу
RU2297420C2 (ru) Средство против кислотоустойчивых бактерий, содержащее гетероциклические производные бензоксазина в качестве активного компонента
AU2015293578B2 (en) Phenyl and tertbutylacetic acid substituted pyridinones having anti-HIV effects
AU2016239209A1 (en) Novel heterocyclic compounds and their use in preventing or treating bacterial infections
EP3144311A1 (en) Tricyclic heterocyclic derivative having hiv replication-inhibiting effect
JP2012149054A (ja) Ｎ−置換−環状アミノ誘導体からなる医薬
JP7773522B2 (ja) 血漿カリクレイン阻害薬
NO20072712L (no) Farmasoytisk preparat for behandling av konsekvensene av alkoholmisbruk, hepatitt, pankreatitt, Alzheimer's sykdom, Parkinsons sykdom, toksisk nyresykdom, reperfusjonsskade, arteriosklerose og som en antidote mot miljotoksiner og medikamentforgiftning
JP7183455B2 (ja) 抗菌薬としての化合物及びその使用
WO2018175185A1 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
JP2022521474A5 (enExample)
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬